Section one: Contracting authority
one.1) Name and addresses
HEALTH DATA RESEARCH UK
215 Euston Road
LONDON
NW12BE
Country
United Kingdom
Region code
UKI31 - Camden and City of London
Charity Commission (England and Wales)
1194431
Internet address(es)
Main address
one.1) Name and addresses
UK DRI LTD
215 Euston Road
London
Country
United Kingdom
Region code
UKI - London
Charity Commission (England and Wales)
1179589
Internet address(es)
Main address
one.2) Information about joint procurement
The contract involves joint procurement
one.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at
https://www.hdruk.ac.uk/jobs/brain-health-clinical-trials-data-augmentation-service/
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted to the above-mentioned address
one.4) Type of the contracting authority
Other type
Charity in receipt of public funding
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Brain Health Clinical Trials Community Assessment for Trials Service
Reference number
HDRUK2024.0413
two.1.2) Main CPV code
- 85323000 - Community health services
two.1.3) Type of contract
Services
two.1.4) Short description
Health Data Research UK (HDR UK) and the UK Dementia Research Institute (UK DRI) invite expressions of interest for the provision of a Brain Health Clinical Trials Community Assessment for Trials Service. The service is a critical component of the Dementia Trials Accelerator (DTA) programme which is supported by the Dame Barbara Windsor Dementia Goals programme and funded by the Medical Research Council (MRC).
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.2) Additional CPV code(s)
- 73110000 - Research services
- 73210000 - Research consultancy services
- 75122000 - Administrative healthcare services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
Programme Vision:
The DTA vision is for the UK to become the destination of choice for late-phase clinical trials in dementia and neurodegenerative diseases. The aims of the DTA are to:
1. Increase trial recruitment by identifying potential participants in trials by creating a "biomarker toolbox". This toolbox will incorporate one or more of: genetic or clinical risk scores, blood-based biomarkers and clinical measurements of subjects living with or at risk of dementia and related neurodegenerative disorders
2. Work with existing UK patient or population cohorts to approach people for clinical trials to identify potential participants
3. Accelerate low-cost delivery identification of potential participants in dementia and neurodegenerative trials with community-based, digitally enabled, trial pre-screening
4. Accelerate collaborative neurodegenerative research through assembly of a secure UK-wide AI-enabled data platform that makes multi-dimensional FAIR (findable, accessible, interoperable, reusable) through trustworthy and secure data environment(s)
5. Prioritise the needs of industry innovators, patients and the public with an iterative engagement with stakeholders
Service Required:
The Brain Health Clinical Trials Community Assessment for Trials Service is central to this vision. It will provide pre-screening for a range of dementia and neurodegenerative clinical trials close to where people live as recommended by the O'Shaughnessy Review. The appointed provider will deliver comprehensive services, including:
• Participant appointment and consent management
• Blood sample collection by community-based phlebotomy services
• Secure preparation, storage, and transportation of samples to designated UK locations
• Data collection and secure sharing with contracting authorities
The service required will be a pilot, initially operating across 4-10 locations in England, Scotland, and Wales, with plans to expand to underserved areas. The aim is to identify up to 10,000 potential trial participants over one year.
Providers must ensure accessibility by offering flexible appointment times, including evenings, weekends, and bank holidays. They must also comply with regulatory standards for sample handling, participant confidentiality, and data security.
This procurement marks the first phase of a broader initiative.
two.2.14) Additional information
HDR UK and UK DRI wish to invite interested providers to engage with us prior to a procurement in early 2025. The purpose of engagement will be to gain provider input into:
• Determine the level of provider interest
• Inform development of service specification/s and collaborative service delivery options
• Procurement process design
• Help enable providers to participate in the process
• Help inform the commercial model and contract terms
HDR UK and UK DRI are preparing a pre-recorded session to provide additional details. Please check the link referenced above on Wednesday, 11th December, for more information.
One-to-one meetings will be scheduled throughout December 2024 and January 2025 for deeper discussions as required at authority sole discretion.
two.3) Estimated date of publication of contract notice
24 January 2025
Section four. Procedure
four.1) Description
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
Section six. Complementary information
six.3) Additional information
HDR UK and UK DRI invite interested parties to express their interest and engage with this market engagement process. This notice serves as an opportunity for providers to refine service specifications collaboratively before the formal procurement process begins.
To respond to this invitation and participate in market engagement, please email procurement@hdr.ac.uk referencing Dementia Trials Accelerator.
six.4) Procedures for review
six.4.1) Review body
Public Procurement Review Service (Cabinet Office)
London
Country
United Kingdom